Adoram Therapeutics: Funding, Investors & Team (Oct 2026)
Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
Adoram Therapeutics has raised $1.4M across 3 funding rounds on record, the most recent an undisclosed round of $1.3M announced in May 2025.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adoram Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
Adoram Therapeutics Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Adoram Therapeutics raised $120k in an undisclosed round announced in Oct 2024.
4 months later, a Pre-Seed was announced in Feb 2025 with no disclosed amount.
3 months later, an undisclosed round of $1.3M was announced in May 2025.
Adoram Therapeutics Founders and Leadership Team
Contact details for the Adoram Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Adoram Therapeutics Funding Compared to Other Biotechnology Startups
Adoram Therapeutics' latest round of $1.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adoram Therapeutics in Biotechnology and Swiss
Companies Similar to Adoram Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Adoram Therapeutics Funding FAQs
What does Adoram Therapeutics do?
Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
How much funding has Adoram Therapeutics raised?
Adoram Therapeutics has raised $1.4M across 3 rounds on record. The most recent is an undisclosed round of $1.3M announced in May 2025.
When did Adoram Therapeutics last raise funding?
Adoram Therapeutics' most recent funding round on record is an undisclosed round of $1.3M, announced in May 2025.
Who founded Adoram Therapeutics?
FundedIQ lists Hesham Hamed (Founder), Leonardo Scapozza (Founder) at Adoram Therapeutics.
Where is Adoram Therapeutics headquartered?
Adoram Therapeutics is based in Swiss, West Virginia, United States.
How many employees does Adoram Therapeutics have?
Adoram Therapeutics is in the 1-10 employee band.
How does Adoram Therapeutics' funding compare to other Biotechnology startups?
Adoram Therapeutics' latest round of $1.3M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Adoram Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adoram Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.